Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.,The Lancet Haematology

当前位置： X-MOL 学术 › Lancet Haematol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
The Lancet Haematology ( IF 15.4 ) Pub Date : 2020-06-18 , DOI: 10.1016/s2352-3026(20)30205-2
Amer M Zeidan ₁ , Prajwal C Boddu ₁ , Mrinal M Patnaik ₂ , Jan Philipp Bewersdorf ₁ , Maximilian Stahl ₃ , Raajit K Rampal ₃ , Rory Shallis ₁ , David P Steensma ₄ , Michael R Savona ₅ , Mikkael A Sekeres ₆ , Gail J Roboz ₇ , Daniel J DeAngelo ₄ , Andre C Schuh ₈ , Eric Padron ₉ , Joshua F Zeidner ₁₀ , Roland B Walter ₁₁ , Francesco Onida ₁₂ , Amir Fathi ₁₃ , Amy DeZern ₁₄ , Gabriela Hobbs ₁₃ , Eytan M Stein ₃ , Paresh Vyas ₁₅ , Andrew H Wei ₁₆ , David T Bowen ₁₇ , Pau Montesinos ₁₈ , Elizabeth A Griffiths ₁₉ , Amit K Verma ₂₀ , Alla Keyzner ₂₁ , Michal Bar-Natan ₂₁ , Shyamala C Navada ₂₁ , Marina Kremyanskaya ₂₁ , Aaron D Goldberg ₃ , Aref Al-Kali ₂ , Mark L Heaney ₂₂ , Aziz Nazha ₂₃ , Huda Salman ₂₄ , Selina Luger ₂₅ , Keith W Pratz ₂₅ , Heiko Konig ₂₆ , Rami Komrokji ₉ , Michael Deininger ₂₇ , Blanca Xicoy Cirici ₂₈ , Vijaya Raj Bhatt ₂₉ , Lewis R Silverman ₂₁ , Harry P Erba ₃₀ , Pierre Fenaux ₃₁ , Uwe Platzbecker ₃₂ , Valeria Santini ₃₃ , Eunice S Wang ₁₉ , Martin S Tallman ₃ , Richard M Stone ₄ , John Mascarenhas ₂₁

Affiliation

Section of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
Department of Hematology, Mayo Clinic, Rochester, MN, USA.
Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Hematology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Hematology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
Department of Hematology and Oncology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.
Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Division of Hematology and Oncology, Lineberger Comprehensive Care Center, University of North Carolina, Chapel Hill, NC, USA.
Division of Hematology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Hematology, IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Department of Hematology, Centre for Leukemia, Massachusetts General Hospital, Boston, MA, USA.
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
MRC Molecular Haematology Unit, BRC Oxford Department of Haematology, University of Oxford, Oxford, UK.
Department of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australia.
Department of Haematology, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK.
Department of Haematology, Hospital Universitario y Politecnico La Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, University of Valencia, Madrid, Spain.
Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.
Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Hematology, Herbert Irving Comprehensive Care Centre, Columbia University, New York, NY, USA.
Department of Hematology, Cleveland Clinic-Taussig Cancer Institute, Cleveland, OH, USA.
Department of Internal Medicine, Stony Brook University Cancer Center, Stony Brook, NY, USA.
Department of Medicine, Hematology and Oncology Division, University of Pennsylvania, Philadelphia, PA, USA.
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, Indiana University, Indianapolis, IN, USA.
Huntsman Cancer Institute, Department of Medicine, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA.
Clinical Haematology Department, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Fred and Pamela Buffett Cancer Center, Department of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA.
Duke Cancer Institute, Department of Medicine, Division of Hematologic Malignancies and Cellular Therapies, Durham, NC, USA.
Department of Hematology, Hôpital St Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; Department of Haematology, Paris University, Paris, France.
Department of Medicine, Division of Translational Hematology, Leipzig University Hospital, Leipzig, Germany.
Department of Medicine, University of Florence Medical School, Florence, Italy.

The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.

中文翻译：

COVID-19 时代急性白血病和髓系肿瘤成人患者管理的特殊考虑因素：国际专家小组的建议。

由严重急性呼吸综合征冠状病毒 2 引起的持续的 COVID-19 大流行是一场全球公共卫生危机。多项观察结果表明，癌症患者的感染后结果比一般人群更差。在此，我们强调在 COVID-19 大流行期间护理急性白血病和骨髓肿瘤患者所面临的挑战。我们总结了与服务分配、临床和支持性护理、临床试验参与以及对这些患者使用救生措施的伦理考虑相关的关键变化。我们认识到，这些建议可能更适用于高收入国家，但由于医疗保健基础设施、个人情况以及复杂且高度流动的医疗保健环境的地区差异，可能无法普遍适用。尽管存在这些限制，我们的目标是根据国际专家的建议，为 COVID-19 大流行期间急性白血病和髓系肿瘤患者的护理提供一个总体框架。

更新日期：2020-06-18

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文